172 related articles for article (PubMed ID: 25286759)
1. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients.
Xu L; Zhao Q; Huang S; Li S; Wang J; Li Q
Tumour Biol; 2015 Feb; 36(2):669-73. PubMed ID: 25286759
[TBL] [Abstract][Full Text] [Related]
2. Serum C-reactive protein and overall survival of patients with osteosarcoma.
Li X; Tian F; Wang F; Li Y
Tumour Biol; 2015 Jul; 36(7):5663-6. PubMed ID: 25986475
[TBL] [Abstract][Full Text] [Related]
3. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
[TBL] [Abstract][Full Text] [Related]
5. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder.
Eggers H; Seidel C; Schrader AJ; Lehmann R; Wegener G; Kuczyk MA; Steffens S
Med Oncol; 2013 Dec; 30(4):705. PubMed ID: 24005810
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer.
Ma YY; Wang H; Zhao WD; Li YF; Wang JJ; Chen XY; Huang YQ; Wang WJ; Wang Y; Sun SC
Cancer Control; 2022; 29():10732748211053150. PubMed ID: 34989251
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
8. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Topolcan O; Racek J; Minarik M; Benesova L; Bortlicek Z; Poprach A; Buchler T
Tumour Biol; 2015 Dec; 36(12):9215-22. PubMed ID: 26088452
[TBL] [Abstract][Full Text] [Related]
9. Cumulative score based on preoperative plasma fibrinogen and serum C-reactive protein could predict long-term survival for esophageal squamous cell carcinoma.
Tian R; Yan H; Zhang F; Sun P; Wu AR; Zhang M; Jiang YL; Wu J; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
Oncotarget; 2016 Sep; 7(38):61533-61543. PubMed ID: 27517497
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Propensity Score Matched Study of the Preoperative C-Reactive Protein to Albumin Ratio and Prognosis in Patients with Resectable Non-Metastatic Breast Cancer.
Zhou L; Ma S; Balde AI; Han S; Cai Z; Li Z
Med Sci Monit; 2019 Jun; 25():4342-4352. PubMed ID: 31182704
[TBL] [Abstract][Full Text] [Related]
11. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients.
Mao M; Wang X; Sheng H; Liu Y; Zhang L; Dai S; Chi PD
BMC Cancer; 2018 Nov; 18(1):1178. PubMed ID: 30486825
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.
Prins RC; Rademacher BL; Mongoue-Tchokote S; Alumkal JJ; Graff JN; Eilers KM; Beer TM
Urol Oncol; 2012; 30(1):33-7. PubMed ID: 20207556
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of serum C-reactive protein levels in patients with metastatic or locally recurrent gastric cancer.
Chen Z; Sun Y; Wang J; Shen X; Chen L; Zhuang Z
Int J Biol Markers; 2016 Jul; 31(3):e294-9. PubMed ID: 27174235
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
Int J Clin Oncol; 2013 Oct; 18(5):884-9. PubMed ID: 22886358
[TBL] [Abstract][Full Text] [Related]
16. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
